Notably, patient 17 was sampled after olaparib resistance in March 2018, and his cfDNA revealed 11 cancer cell populations with somatic deletions or mutations reversing the germline BRCA2 stop gain (Fig 3C).26 These alterations were not reported by Guardant360, likely because it only reports short indels. This evidence concerns the gene BRCA2 and cancer.